BACKGROUND: Adolescents represent the fastest growing demographic group of new human immunodeficiency virus (HIV) infections in the United States. At present, there is little information available about their response to therapy. METHODS: We studied 120 adolescents infected via high-risk behaviors who began receiving highly active antiretroviral therapy (HAART), to determine their virologic and immunologic response to therapy. RESULTS: Subjects were enrolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group. After 16-24 weeks of HAART, 59% of subjects had reproducible undetectable virus loads, according to repeat measurements (virologic success). As enumerated by flow-cytometric analysis, increases in levels of CD4 helper cells (both naive and memory) and decreases in levels of CD8 suppressor cells were observed. Partial restoration of some immunologic parameters for patients who did not achieve virologic success was also observed, but to a more limited extent than for adolescents with virologic success. Adherence to HAART was the only predictor of achieving undetectable virus loads. CONCLUSIONS: Adolescents have the capacity to improve their immunologic status with HAART. Lower than expected success in virologic control is related to lack of adherence, and efforts to improve treatment outcome must stress measures to assure adherence to medication.
BACKGROUND: Adolescents represent the fastest growing demographic group of new human immunodeficiency virus (HIV) infections in the United States. At present, there is little information available about their response to therapy. METHODS: We studied 120 adolescents infected via high-risk behaviors who began receiving highly active antiretroviral therapy (HAART), to determine their virologic and immunologic response to therapy. RESULTS: Subjects were enrolled at 28 sites of the Pediatric Acquired Immunodeficiency Syndrome Clinical Trials Group. After 16-24 weeks of HAART, 59% of subjects had reproducible undetectable virus loads, according to repeat measurements (virologic success). As enumerated by flow-cytometric analysis, increases in levels of CD4 helper cells (both naive and memory) and decreases in levels of CD8 suppressor cells were observed. Partial restoration of some immunologic parameters for patients who did not achieve virologic success was also observed, but to a more limited extent than for adolescents with virologic success. Adherence to HAART was the only predictor of achieving undetectable virus loads. CONCLUSIONS: Adolescents have the capacity to improve their immunologic status with HAART. Lower than expected success in virologic control is related to lack of adherence, and efforts to improve treatment outcome must stress measures to assure adherence to medication.
Authors: Jaime Martinez; Gary Harper; Russell A Carleton; Sybil Hosek; Kelly Bojan; Gretchen Clum; Gretchen Glum; Jonathan Ellen Journal: AIDS Patient Care STDS Date: 2011-12-07 Impact factor: 5.078
Authors: Allison L Agwu; John A Fleishman; P Todd Korthuis; George K Siberry; Jonathan M Ellen; Aditya H Gaur; Richard Rutstein; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2011-09-01 Impact factor: 3.731
Authors: Bret J Rudy; John Sleasman; Bill Kapogiannis; Craig M Wilson; James Bethel; Leslie Serchuck; Sushma Ahmad; Coleen K Cunningham Journal: AIDS Res Hum Retroviruses Date: 2009-06 Impact factor: 2.205
Authors: Macarthur Charles; Francine Noel; Paul Leger; Patrice Severe; Cynthia Riviere; Carole Anne Beauharnais; Erica Miller; John Rutledge; Heejung Bang; Wesley Shealey; Richard T D'Aquila; Roy M Gulick; Warren D Johnson; Peter F Wright; Jean William Pape; Daniel W Fitzgerald Journal: Bull World Health Organ Date: 2008-12 Impact factor: 9.408
Authors: Elizabeth J Letourneau; Deborah A Ellis; Sylvie Naar-King; Jason E Chapman; Phillippe B Cunningham; Sandra Fowler Journal: AIDS Care Date: 2012-08-22